Safe-T: Private Investment of NIS 22.5M supports positive momentum that is in line with company’s strategy. Target price raised to NIS 9.38 Post author:jaimeuss_admin Post published:17 בSeptember 2018 Post category:Research Continue ReadingSafe-T: Private Investment of NIS 22.5M supports positive momentum that is in line with company’s strategy. Target price raised to NIS 9.38
RedHill Biopharma Ltd.: The acceleration of RHB-104 Phase III Study in Crohn’s disease increases company value and share price. Post author:jaimeuss_admin Post published:17 בSeptember 2018 Post category:Research Continue ReadingRedHill Biopharma Ltd.: The acceleration of RHB-104 Phase III Study in Crohn’s disease increases company value and share price.
DNA Biomedical Solutions Ltd.: The company and its holdings can become a major force in the osteoporosis care market, pending success in next year’s clinical trials. Post author:jaimeuss_admin Post published:6 בSeptember 2018 Post category:Research Continue ReadingDNA Biomedical Solutions Ltd.: The company and its holdings can become a major force in the osteoporosis care market, pending success in next year’s clinical trials.
Vonetize Plc: Investment Opportunity in VOD for Emerging Countries and Israel; Agreement with Triple C is Expected to Significantly Increase Vonetize Revenues Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingVonetize Plc: Investment Opportunity in VOD for Emerging Countries and Israel; Agreement with Triple C is Expected to Significantly Increase Vonetize Revenues
Safe-T: Private Investment of NIS 22.5M supports positive momentum that is in line with company’s strategy. Target price raised to NIS 9.38 Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingSafe-T: Private Investment of NIS 22.5M supports positive momentum that is in line with company’s strategy. Target price raised to NIS 9.38
